Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins
- 28 April 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 17 (5) , 1259-1268
Abstract
Targeted protein degradation is a promising therapeutic strategy capable of overcoming the limitations of traditional occupancy-based inhibitors. By ablating all of the associated functions of a protein at once, the event-driven pharmacology of degrader technologies has recently enabled the targeting of proteins that have been historically deemed "undruggable". Most degradation strategies utilize the ubiquitin-proteasome system to mediate intracellular target degradation and are thus limited to targeting proteins with cytoplasmic domains. While some of these strategies, such as PROTACs, have shown great promise, there is a need for new modalities that can be applied to specifically target cell surface proteins. We previously described the development of an antibody-based PROTAC (AbTAC) that utilizes genetically encoded IgG bispecific antibody scaffolds to bring the cell surface E3-ligase RNF43 into the proximity of a membrane protein of interest (POI) to mediate its degradation. Here, we employ rational protein engineering strategies to interrogate and optimize the properties necessary for efficient degradation of two therapeutically important membrane proteins, PD-L1 and EGFR. We develop multiple antibodies to RNF43 and show that the specific antibody binding epitopes on RNF43 and the POI are more important than the affinities of the AbTAC antibodies. We further expand the available repertoire of E3 ligases by co-opting the E3-ligase ZNRF3 to degrade both PD-L1 and EGFR and show similar importance of epitope for degradation efficiency. Importantly, we show that both RNF43 and ZNRF3 AbTACs do not potentiate unwanted WNT signaling. Lastly, we find that these AbTACs can be even further improved by exploring various dual-binding and IgG scaffolds that range in flexibility, valency, and orientation of the binding arms. These structure-activity and mechanistic studies provide a roadmap for optimizing the development of AbTACs, thereby greatly expanding their utility for targeted cell surface protein degradation.Keywords
Funding Information
- National Cancer Institute (1F31CA265080-01, R01CA248323)
- National Institutes of Health (R35GM122451)
- Harry and Dianna Hind Endowed Chair Professorship
- Chan Zuckerberg Biohub Investigator Program
This publication has 25 references indexed in Scilit:
- A High Through-put Platform for Recombinant Antibodies to Folded ProteinsMolecular & Cellular Proteomics, 2015
- Bispecific T‐cell engagers for cancer immunotherapyImmunology & Cell Biology, 2014
- Revisiting the Role of Glycosylation in the Structure of Human IgG FcACS Chemical Biology, 2012
- ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive mannerNature, 2012
- Small-molecule inhibition of Wnt signaling through activation of casein kinase 1αNature Chemical Biology, 2010
- Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor ConformationCancer Research, 2009
- Therapeutic antibodies: successes, limitations and hopes for the futureBritish Journal of Pharmacology, 2009
- Antibodies specifically targeting a locally misfolded region of tumor associated EGFRProceedings of the National Academy of Sciences, 2009
- Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for DimerizationCancer Cell, 2008
- ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerizationProtein Engineering, Design and Selection, 1996